Press releases
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
- Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
- Actym Therapeutics Appoints Thomas Smart as CEO
More ▼
Key statistics
As of last trade Precigen Inc (I5X:DEU) traded at 1.36, -19.94% below its 52-week high of 1.70, set on Aug 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.42 |
Low | 1.33 |
Bid | 1.35 |
Offer | 1.40 |
Previous close | 1.36 |
Average volume | 58.80 |
---|---|
Shares outstanding | 252.42m |
Free float | 223.44m |
P/E (TTM) | -- |
Market cap | 371.06m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼